Date: 2013-04-26
Type of information: Grant
Company: The Biomargin consortium consists of INSERM (France), INSERM Transfert SA IT, (France), Assistance publique - Hôpitaux de Paris (AP – HP) (France, CEA (France), CNRS (France), Katholieke Universiteit Leuven (Belgium),Vlaamse Instelling voor Technologisch Onderzoek -Vito, (Belgium), Mosaiques diagnostics (Germany), Medizinische Hochschule Hanover (Germany), Cardinal Systems (France), Université Paris Descartes (France), AcureOmics (Sweden), Centre hospitalier universitaire de Limoges (France).
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: € 6 million
Funding type: grant
Planned used:
Others: The BIOMARGIN (BIOMArkers of Renal Graft INjuries in kidney allograft recipients) project has been granted an European Union award of € 6 million to support the development of more effective, non-invasive methods to prevent and diagnose lesions in transplanted kidneys so as to improve treatment and the long-term survival of the graft.
Thirteen European research teams located in France (Inserm, AP-HP, CEA, CNRS, Université Paris Descartes, CHU de Limoges), Belgium, Germany and Sweden will work together on a so-called \"omics\" innovative approach involving the simultaneous study of a large number of genes, proteins and metabolites in order to identify biomarkers for these lesions on a large scale.The purpose of the BIOMARGIN project is to:
• Discover, select and validate biomarkers of lesions in grafted kidneys, as indicated from the blood and/or urine samples of adult and child renal transplant patients.
• Provide doctors with non-invasive and reliable diagnostic tests, as well as interpretation algorithms enabling more accurate and more predictive monitoring of transplant patients than at present.
• Avoid or reduce the use of biopsies and improve treatment, patient quality of life and graft long-term survival.
• Understand the mechanisms involved in the process by which lesions occur in the graft which, combined with mass spectrometry imaging, should provide pathologists with new molecular targets and tools for analysing renal graft biopsies.
The study will consist of four phases:
• Phase 1: retrospective, case-control study of samples stored in the biobanks maintained by the partners (CHU Limoges, Necker Children\'s Hospital, MHH Hanover, KU Leuven), aimed at finding an extensive list of candidate biomarkers.
• Phase 2: selection of biomarkers with good diagnostic performance for histological lesions in the graft.
• Phase 3: validation of the diagnostic performance of biomarker candidates in a representative sample of transplant patients.
• Phase 4: validation of the biomarker diagnostic and prognostic performance in newly transplanted kidney recipients recruited for the project.
Therapeutic area: Transplantation - Renal diseases - Kidney diseases
